AstraZeneca and Ionis claim a PCSK9 win, but will it matter in a crowded market?

The first generation of PCSK9 blockers was, roughly speaking, a commercial disaster for their developers, Sanofi and Amgen. Although they successfully lowered bad cholesterol and prevented heart attacks and strokes by a new mechanism, insurers were unwilling to pay the high cost of the medications and patients seemed less than…

Click to view original post